Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

KITE PHARMA, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 2009-01-01

Employees: 1K

Market Cap: -

Website: http://www.kitepharma.com

Clinical Trials

A Study of KITE-363 in Participants With Refractory Autoimmune Diseases

Phase 1

Not yet recruiting

Conditions: Systemic Lupus Erythematosus
Lupus Nephritis
Systemic Sclerosis
Idiopathic Inflammatory Myopathy

Interventions: Biological: KITE-363
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2025-06-26

Last Posted Date: 2025-06-26

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 52

Registration Number: NCT07038447

A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

Phase 3

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Anitocabtagene Autoleucel
Drug: Pomalidomide
Drug: Cyclophosphamide
Drug: Bortezomib
Drug: Fludarabine
Drug: Dexamethasone
Drug: Daratumumab
Drug: Carfilzomib

First Posted Date: 2024-05-14

Last Posted Date: 2025-07-01

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 450

Registration Number: NCT06413498

Locations: 🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
UC San Diego Moores Cancer Center, San Diego, California, United States

and more 72 locations

Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia

Phase 2

Recruiting

Conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Relapsed/Refractory Mantle Cell Lymphoma

Interventions: Drug: KTE-X19
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2024-02-12

Last Posted Date: 2025-03-26

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 21

Registration Number: NCT06253663

Locations: 🇯🇵
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital, Tokyo, Japan
🇯🇵
Chiba University Hospital, Chiba, Japan
🇯🇵
Kyushu University Hospital, Fukuoka, Japan

and more 6 locations

Study of KITE-197 in Participants With Relapsed or Refractory Large B-cell Lymphoma

Phase 1

Recruiting

Conditions: Relapsed/Refractory Large B-cell Lymphoma

Interventions: Drug: KITE-197
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2023-10-12

Last Posted Date: 2025-05-29

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 39

Registration Number: NCT06079164

Locations: 🇺🇸
Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸
Henry-Joyce Cancer Clinic, Nashville, Tennessee, United States

and more 9 locations

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

Conditions: Large B-cell Lymphoma
Follicular Lymphoma

First Posted Date: 2023-03-20

Last Posted Date: 2025-06-22

Lead Sponsor: Kite, A Gilead Company

Registration Number: NCT05776160

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
City of Hope Medical Center, Duarte, California, United States

and more 110 locations

Expanded Access Study for the Treatment of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

Conditions: Mantle Cell Lymphoma
Acute Lymphoblastic Leukemia

First Posted Date: 2023-03-20

Last Posted Date: 2025-01-10

Lead Sponsor: Kite, A Gilead Company

Registration Number: NCT05776134

Locations: 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States

and more 41 locations

Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma

Phase 3

Recruiting

Conditions: High-risk Large B-cell Lymphoma (LBCL)

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Rituximab
Drug: Fludarabine
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2022-11-04

Last Posted Date: 2025-05-18

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 300

Registration Number: NCT05605899

Locations: 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸
Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
🇺🇸
Mayo Clinic, Phoenix, Arizona, United States

and more 87 locations

Study of Brexucabtagene Autoleucel in Adults With Rare B-cell Malignancies

Phase 2

Terminated

Conditions: Relapsed/Refractory Hairy Cell Leukemia
Relapsed/Refractory Burkitt Lymphoma
Relapsed/Refractory Waldenstrom Macroglobulinemia
Relapsed/Refractory Richter Transformation

Interventions: Biological: Brexucabtagene Autoleucel
Drug: Cyclophosphamide
Drug: Fludarabine

First Posted Date: 2022-09-13

Last Posted Date: 2025-03-03

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 19

Registration Number: NCT05537766

Locations: 🇺🇸
City of Hope (City of Hope National Medical Center), Duarte, California, United States
🇺🇸
Stanford Cancer Institute, Stanford, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 23 locations

Study of Axicabtagene Ciloleucel Given With Steroids In Participants With Relapsed Or Refractory Large B-Cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Relapsed or Refractory Large B-cell Lymphoma

Interventions: Biological: Axicabtagene Ciloleucel
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Dexamethasone

First Posted Date: 2022-07-15

Last Posted Date: 2024-10-04

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 30

Registration Number: NCT05459571

Locations: 🇺🇸
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇺🇸
UCLA, Los Angeles, California, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 13 locations

Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Biological: anitocabtagene-autoleucel

First Posted Date: 2022-05-31

Last Posted Date: 2024-04-15

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 110

Registration Number: NCT05396885

Locations: 🇺🇸
Honor Health, Scottsdale, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸
Colorado Blood Cancer Institute, Denver, Colorado, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy